Trial Search Results

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Janssen Biotech, Inc.

Collaborator: Pharmacyclics LLC.

Stanford Investigator(s):

Intervention(s):

  • Drug: Ibrutinib

Eligibility


Inclusion Criteria:

   - Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or
   refractory disease after prior therapy are eligible.

Exclusion Criteria:

   - Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are
   not eligible.

   - Patients previously treated with ibrutinib are not eligible.

   - Patients enrolled in another interventional clinical study with therapeutic intent are
   not eligible.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting